



- (51) **International Patent Classification:**
A61K 31/4545 (2006.01) *A61K 35/14* (2015.01)
- (21) **International Application Number:**
PCT/US2018/038529
- (22) **International Filing Date:**
20 June 2018 (20.06.2018)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/523,147 21 June 2017 (21.06.2017) US
15/538,620 21 June 2017 (21.06.2017) US
- (71) **Applicant: ICELL GENE THERAPEUTICS LLC**
[US/US]; 25 Health Sciences Drive, Stony Brook, NY 11790 (US).
- (72) **Inventors: MA, Yupo;** iCell Gene Therapeutics LLC, 25 Health Sciences Drive, Stony Brook, NY 11790 (US). **PINZ, Kevin;** iCell Gene Therapeutics LLC, 25 Health Sciences Drive, Stony Brook, NY 11790 (US). **JIANG, Xun;** iCell Gene Therapeutics LLC, 25 Health Sciences Drive, Stony Brook, NY 11790 (US). **WADA, Masayuki;** iCell

Gene Therapeutics LLC, 25 Health Sciences Drive, Stony Brook, NY 11790 (US). **CHEN, Kevin;** iCell Gene Therapeutics LLC, 25 Health Sciences Drive, Stony Brook, NY 11790 (US).

- (74) **Agent: WOO, Perry, Y. et al.;** Hoffmann & Baron, LLP, 6900 Jericho Turnpike, Syosset, NY 11791 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

- (54) **Title:** CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF




FIGURE 1

- (57) **Abstract:** The present disclosure provides chimeric antigen receptors, compositions, and methods thereof. In one embodiment the present disclosure provides a method of treating autoimmune diseases, asthma, and preventing or mediating organ rejection in a subject.

[Continued on next page]

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*